| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
AZ044 targets PI4KIIIα (phosphatidylinositol 4-kinase III alpha), an enzyme involved in the synthesis of phosphatidylinositol 4-phosphate (PI4P), a key lipid signaling molecule. It exhibits high potency in inhibiting PI4KIIIα with an IC50 of 1.0 nM. It also shows moderate inhibition of PI4KIIIβ with an IC50 of 251.19 nM. Additionally, AZ044 inhibits PI3Kα/β/γ/δ, though with lower potency.
|
|---|---|
| ln Vitro |
In vitro, AZ044 demonstrates potent bioactivity as an inhibitor of various kinases and phosphatidylinositol enzymes. It exhibits high potency in inhibiting PI4KIIIα with an IC50 of 1.0 nM and moderate inhibition of PI4KIIIβ with an IC50 of 251.19 nM. The compound's selectivity for PI4KIIIα over other lipid kinases makes it a valuable tool for studying PI4P signaling.
|
| ln Vivo |
Specific in vivo data for AZ044 are not detailed in the available literature. However, as a potent and selective inhibitor of PI4KIIIα, it is expected to be used in preclinical studies to investigate the role of PI4KIIIα in various biological processes and disease models, including cancer and viral infections.
|
| Enzyme Assay |
The enzymatic activity of AZ044 can be assessed using kinase assays with recombinant PI4KIIIα and PI4KIIIβ proteins. The assay involves incubating the kinase with its substrate, phosphatidylinositol, and ATP in the presence of varying concentrations of the inhibitor. The production of phosphatidylinositol 4-phosphate is measured using techniques such as radioactive labeling or ELISA-based detection. The IC50 or pIC50 values are determined from dose-response curves.
|
| Cell Assay |
To evaluate the cellular effects of AZ044, cells are treated with the compound, and the levels of phosphatidylinositol 4-phosphate are measured using lipid extraction and analysis. The effects on downstream signaling pathways, such as those involving Akt or mTOR, can be assessed by Western blotting. The compound's effects on cell proliferation, survival, and viral replication can also be evaluated.
|
| Animal Protocol |
In vivo studies with AZ044 would typically involve administration to animals via oral or parenteral routes. Models of cancer, inflammation, or viral infection could be used to evaluate the compound's efficacy. Pharmacodynamic markers, such as PI4P levels in tissues, would be measured to assess target engagement. Pharmacokinetic parameters would also be characterized.
|
| ADME/Pharmacokinetics |
AZ044 has a molecular formula of C24H27N3O3S and a molecular weight of 437.55. Its CAS number is 1800017-49-5. The compound is a white to yellow solid powder with a density of 1.4±0.1 g/cm3. It has a logP of 3.86. The purity is ≥98%. It is soluble in DMSO at ~125 mg/mL. The powder should be stored at -20°C for 3 years or at 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for AZ044 are not detailed in the available literature. As with all research compounds, standard safety precautions should be taken during handling. The compound's selectivity for PI4KIIIα over other lipid kinases may suggest a potentially lower risk of off-target toxicity.
|
| References | |
| Additional Infomation |
AZ044 (PI4K-IN-1) is a potent and selective inhibitor of PI4KIIIα used as a research tool to study PI4P signaling. It is a valuable compound for investigating the role of PI4KIIIα in various cellular processes and disease contexts, including cancer and viral infections. It is not a clinically approved drug.
|
| Molecular Formula |
C24H27N3O3S
|
|---|---|
| Molecular Weight |
437.554484605789
|
| Exact Mass |
437.177
|
| CAS # |
1800017-49-5
|
| PubChem CID |
122184544
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
690.9±65.0 °C at 760 mmHg
|
| Flash Point |
371.6±34.3 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.691
|
| LogP |
3.86
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
757
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(CCC1CNC2=NC3=C(S2)C=C(C=C3)C4=CC(=O)N(C=C4)CC5CC5)C(=O)O
|
| InChi Key |
LCUPEZBPGVQFLN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H27N3O3S/c28-22-12-19(9-10-27(22)14-16-1-2-16)18-7-8-20-21(11-18)31-24(26-20)25-13-15-3-5-17(6-4-15)23(29)30/h7-12,15-17H,1-6,13-14H2,(H,25,26)(H,29,30)
|
| Chemical Name |
4-[[[6-[1-(cyclopropylmethyl)-2-oxopyridin-4-yl]-1,3-benzothiazol-2-yl]amino]methyl]cyclohexane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~285.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2855 mL | 11.4273 mL | 22.8545 mL | |
| 5 mM | 0.4571 mL | 2.2855 mL | 4.5709 mL | |
| 10 mM | 0.2285 mL | 1.1427 mL | 2.2855 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
